title: A synthetic podophyllotoxin derivative exerts anti-cancer effects by inducing mitotic arrest and pro-apoptotic ER stress in lung cancer preclinical models.
abstract: Some potent chemotherapy drugs including tubulin-binding agents had been developed from nature plants, such as podophyllotoxin and paclitaxel. However, poor cytotoxic selectivity, serious side-effects, and limited effectiveness are still the major concerns in their therapeutic application. We developed a fully synthetic podophyllotoxin derivative named Ching001 and investigated its anti-tumor growth effects and mechanisms in lung cancer preclinical models. Ching001 showed a selective cytotoxicity to different lung cancer cell lines but not to normal lung cells. Ching001 inhibited the polymerization of microtubule resulting in mitotic arrest as evident by the accumulation of mitosis-related proteins, survivin and aurora B, thereby leading to DNA damage and apoptosis. Ching001 also activated pro-apoptotic ER stress signaling pathway. Intraperitoneal injection of 2 mg/kg Ching001 significantly inhibited the tumor growth of A549 xenograft, while injection of 0.2 mg/kg Ching001 decreased the lung colonization ability of A549 cells in experimental metastasis assay. These anti-tumor growth and lung colonization inhibition effects were stronger than those of paclitaxel treatment at the same dosage. The xenograft tumor tissue stains further confirmed that Ching001 induced mitosis arrest and tumor apoptosis. In addition, the hematology and biochemistry tests of blood samples as well as tissue examinations indicated that Ching001 treatment did not show apparent organ toxicities in tested animals. We provided preclinical evidence that novel synthetic microtubule inhibitor Ching001, which can trigger DNA damage and apoptosis by inducing mitotic arrest and ER stress, is a potential anti-cancer compound for further drug development.
authors: Institute of Basic Medical Sciences, National Cheng Kung University, Tainan, Taiwan, R.O.C.
authors: Jia-Yang
authors: JY
authors: Chen
authors: Yen-An
authors: YA
authors: Tang
authors: Wen-Shan
authors: WS
authors: Li
authors: Yu-Ching
authors: YC
authors: Chiou
authors: Jiunn-Min
authors: JM
authors: Shieh
authors: Yi-Ching
authors: YC
authors: Wang
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D059447:Cell Cycle Checkpoints / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004249:DNA Damage / Q000187:drug effects; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D059865:Endoplasmic Reticulum Stress / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D059566:M Phase Cell Cycle Checkpoints / Q000187:drug effects; D051379:Mice; D008870:Microtubules / Q000378:metabolism; D008938:Mitosis / Q000187:drug effects*; D008954:Models, Biological; D011034:Podophyllotoxin / Q000031:analogs & derivatives / Q000494:pharmacology* / Q000633:toxicity; D055503:Protein Multimerization / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D011034:Podophyllotoxin
references: Leuk Res. 1992;16(1):61-5
references: 1732675
references: Med Res Rev. 1998 Sep;18(5):299-314
references: 9735871
references: Curr Opin Cell Biol. 2011 Apr;23(2):143-9
references: 21146390
references: Med Res Rev. 1998 Sep;18(5):315-31
references: 9735872
references: Mini Rev Med Chem. 2011 Sep;11(10):901-9
references: 21781026
references: Pharmacol Ther. 1993 Aug;59(2):163-228
references: 8278462
references: Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55
references: 9748598
references: Biochimie. 1998 Mar;80(3):207-22
references: 9615861
references: Am J Surg Pathol. 2006 Jan;30(1):83-9
references: 16330946
references: J Cell Biol. 2007 Jun 18;177(6):1017-27
references: 17562790
references: Mol Pharmacol. 2004 Jan;65(1):77-84
references: 14722239
references: Biochem Biophys Res Commun. 2012 Feb 24;418(4):736-41
references: 22306008
references: Cancer Res. 2001 Jul 1;61(13):5223-30
references: 11431363
references: Nat Rev Mol Cell Biol. 2003 Nov;4(11):842-54
references: 14625535
references: Cancer Res. 2004 Jul 1;64(13):4621-8
references: 15231674
references: Mini Rev Med Chem. 2009 Nov 1;9(13):1547-55
references: 20205636
references: J Clin Oncol. 2009 May 20;27(15):2530-5
references: 19349543
references: Apoptosis. 2003 Oct;8(5):413-50
references: 12975575
references: Philos Trans R Soc Lond B Biol Sci. 2011 Dec 27;366(1584):3584-94
references: 22084385
references: Nat Rev Cancer. 2010 Mar;10(3):194-204
references: 20147901
references: Oncogene. 2004 Aug 26;23(39):6548-58
references: 15221012
references: Curr Med Chem Anticancer Agents. 2002 Jan;2(1):71-90
references: 12678752
references: Sex Transm Dis. 2011 Mar;38(3):216-8
references: 20938374
references: Nat Rev Drug Discov. 2010 Oct;9(10):790-803
references: 20885410
references: Ann Oncol. 2007 Jul;18 Suppl 5:v3-8
references: 17656560
references: Cancer Treat Rev. 2006 Apr;32(2):106-18
references: 16473470
references: J Struct Biol. 1999 Dec 15;128(2):211-5
references: 10600574
references: Nature. 2012 Jan 18;482(7383):53-8
references: 22258507